- Conditions
- RSV Infection
- Interventions
- Candidate vaccine, SCB-1019T, AREXVY, placebo
- Biological · Other
- Lead sponsor
- Clover Biopharmaceuticals USA, LLC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Not listed
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 21 Months
- Enrollment
- 344 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • Cleveland, Ohio
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- D46/NS2/N/ΔM2-2-HindIII, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MEDI ΔM2-2 vaccine, Placebo vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 49 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSVpreF MDV, RSVpreF SDV
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 453 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 6
- States / cities
- South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- 200 mg RV521/78 µCi [ 14C]-RV521.
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Drug Safety
- Interventions
- MDT-637
- Drug
- Lead sponsor
- MicroDose Therapeutx, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- RSV Infection, QTc Interval
- Interventions
- zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • San Antonio, Texas
- Conditions
- Influenza a, Influenza B, RSV, COVID 19
- Interventions
- LIAISON NES FLU A/B, RSV & COVID-19
- Diagnostic Test
- Lead sponsor
- DiaSorin Molecular LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Henderson, Nevada • Pittsburgh, Pennsylvania • McAllen, Texas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 841 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Coral Gables, Florida • Savannah, Georgia • Evansville, Indiana + 5 more
- Conditions
- RSV Infections
- Interventions
- Not listed
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- Up to 36 Months
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Syracuse, New York • Seattle, Washington
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALS-008176, Placebo
- Drug
- Lead sponsor
- Alios Biopharma Inc.
- Industry
- Eligibility
- Up to 12 Months
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Nasal swab sampling, Blood sampling, Diary cards
- Procedure · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Up to 6 Years
- Enrollment
- 2,409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2021
- U.S. locations
- 9
- States / cities
- Oakland, California • Sacramento, California • Santa Clara, California + 5 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- RSV vaccine formulation 1, RSV vaccine formulation 2, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 18 Months
- Enrollment
- 259 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 25
- States / cities
- Gardena, California • La Mesa, California • Los Angeles, California + 21 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 770 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Waterbury, Connecticut • Brooksville, Florida • Immokalee, Florida + 6 more
- Conditions
- COVID-19 Respiratory Infection, Influenza A, Influenza Type B, RSV Infection
- Interventions
- Labcorp COVID-19+Flu+RSV Test Home Collection Kit
- Device
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 2 Years to 89 Years
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- D46cpΔM2-2 vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Tract Infections
- Interventions
- Respiratory pathogen panel PCR test, COVID-19 antibody test
- Diagnostic Test
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- JNJ-53718678 500 mg, JNJ-53718678 80 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 13
- States / cities
- Cerritos, California • Chula Vista, California • Garden Grove, California + 10 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Abrysvo, Beyfortus
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
- Conditions
- RSV Infection
- Interventions
- EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 1030s vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose, Placebo
- Biological · Drug
- Lead sponsor
- Blue Lake Biotechnology Inc.
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- La Mesa, California • Modesto, California • Aurora, Colorado + 12 more